Wat is de prijs voor Poseida Therapeutics, Inc. (PSTX)

Het prijs van Poseida Therapeutics, Inc. (PSTX) is $9.50

Wat is de marktkapitalisatie voor Poseida Therapeutics, Inc. (PSTX)

Marktkapitalisatie voorPoseida Therapeutics, Inc. (PSTX) is $819.52M

Poseida Therapeutics, Inc. (PSTX) WPA

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

Jaar	EPS	Wijzigen
2026 (TTM)	$-0.63	-54.01%
2023	$-1.37	53.93%
2022	$-0.89	-1,357.06%
2021	$0.07	68.57%
2020	$0.04	-101.80%
2019	$-2.33	87.90%
2018	$-1.24	153.06%
2017	$-0.49	535.54%
2016	$-0.08	0.00%

Jaar

EPS

Wijzigen

2026 (TTM)

$-0.63

-54.01%

2023

$-1.37

53.93%

2022

$-0.89

-1,357.06%

2021

$0.07

68.57%

2020

$0.04

-101.80%

2019

$-2.33

87.90%

2018

$-1.24

153.06%

2017

$-0.49

535.54%

2016

$-0.08

0.00%

Bedrijf	EPS	EPS-verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-2,849.21%	US
Argenx SE ARGX.US	$27.74	-4,503.17%	NL
CSL Limited CSL.AX	$-5.29	739.68%	AU
Moderna, Inc. MRNA.US	$-7.98	1,166.67%	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

EPS

EPS-verschil

Land